Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

(MedPage Today) -- ORLANDO--For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response rates in updated results...